ERBB2 and breast carcinoma: Loss of PTPN12 promotes in vivo tumor progression of the implanted breast cancer cells, which express a constitutively active form of ErbB2 (CA-ErbB2), and correlates with the impaired feedback regulation of RTKs, thereby resulting in their aberrant activation [15,16].